Clinical Trials Logo

Clinical Trial Summary

The Investigators hypothesise that asthma is not a single disease, but a syndrome resulting from several distinct underlying disease processes known as endotypes. There are approximately 30,000 genes in humans, and each gene is responsible for the production of a particular protein. Using a technique called "whole genome expression profiling" The Investigators have undertaken a small study looking at the activity of all 30,000 genes in the airway tissue of people with asthma. This work has identified 3 mutually exclusive distinct molecular patterns (endotypes) of severe asthma and has identified other potentially important molecular targets (manuscripts in preparation). In particular,the Investigators have found that 25-50% of patients have asthma associated with the activity of proteins called Th2 cytokines (Th2-high asthma). New treatments are in development that target this pathway. However, the Investigators do not know what is driving severe asthma in patients who do not express these Th2 cytokines. The aim of this study is to investigate in more detail the molecular mechanisms driving severe asthma in patients who do not express Th2 cytokines (Th2-low asthma), so that the Investigators can identify new targets for treatment in this group. To do this the Investigators will collect airway tissue via a telescope (bronchoscope), and analyse gene and protein expression in the tissue. The Investigators will then compare the molecular activity between patients with Th2-high and Th2-low asthma, and healthy control subjects (data obtained from a parallel study).


Clinical Trial Description

Asthma is a very common disorder which causes a great deal of distress for patients, and occasionally results in premature death. Approximately 10% of people with asthma have severe disease which is not helped by current treatments; The Investigators need to find new treatments for these patients urgently. Patients with asthma are not all the same, but have distinct features which characterise their asthma.The Investigators therefore hypothesise that asthma is not a single disease, but a syndrome resulting from several distinct underlying disease processes known as endotypes. There are approximately 30,000 genes in humans, and each gene is responsible for the production of a particular protein. Using a technique called "whole genome expression profiling" The Investigators have undertaken a small study looking at the activity of all 30,000 genes in the airway tissue of people with asthma. This work has identified 3 mutually exclusive distinct molecular patterns (endotypes) of severe asthma and has identified other potentially important molecular targets (manuscripts in preparation). In particular, the Investigators have found that 25-50% of patients have asthma associated with the activity of proteins called Th2 cytokines (Th2-high asthma). New treatments are in development that target this pathway. However, the Investigators do not know what is driving severe asthma in patients who do not express these Th2 cytokines. The aim of this study is to investigate in more detail the molecular mechanisms driving severe asthma in patients who do not express Th2 cytokines (Th2-low asthma), so that the Investigators can identify new targets for treatment in this group. To do this the Investigators will collect airway tissue via a telescope (bronchoscope), and analyse gene and protein expression in the tissue. The Investigators will then compare the molecular activity between patients with Th2-high and Th2-low asthma, and healthy control subjects (data obtained from a parallel study). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02883530
Study type Observational
Source University of Leicester
Contact
Status Active, not recruiting
Phase
Start date September 26, 2016
Completion date October 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02513160 - Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma Phase 3
Completed NCT02003521 - Impact of Lung Flute Therapy on Asthma N/A
Completed NCT01253603 - Efficacy, Safety, and Pharmacokinetics of QAW039 Phase 2
Completed NCT01845025 - Study of Safety of Foradil in Patients With Persistent Asthma Phase 4
Not yet recruiting NCT02053402 - Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Phase 4
Completed NCT01078688 - Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma N/A
Completed NCT01156844 - Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol Phase 2
Completed NCT02176694 - Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care N/A
Completed NCT02026336 - E-nose and Inflammatory Asthma Phenotypes N/A
Withdrawn NCT04271839 - Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients Phase 4
Active, not recruiting NCT04480242 - Asthma Research in Children and Adolescents
Completed NCT02175771 - Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Phase 3
Completed NCT01147510 - Asthma Control in Elderly Patients With Montelukast Phase 4
Completed NCT03541187 - Cockroach Immunotherapy in Children and Adolescents Phase 2
Completed NCT02040779 - A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma Phase 3
Active, not recruiting NCT05843045 - Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma N/A